Previous Close | 235.30 |
Open | 238.06 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 237.29 - 240.41 |
52 Week Range | 234.20 - 323.78 |
Volume | |
Avg. Volume | 10,454 |
Market Cap | 192.543B |
Beta (5Y Monthly) | 0.15 |
PE Ratio (TTM) | 15.20 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 10.86 (4.58%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | N/A |
CQDM is proud to announce the funding of a collaborative research project to identify biomarkers and therapeutic solutions for diabetic kidney disease (DKD), one of the leading causes of kidney failure. This project, with a total value of over $9.4M, is made possible thanks to a $1.5M grant from the Quebec government (MEIE) awarded by CQDM, as well as a $2.4M financial contribution from Hoffmann-La Roche Limited (Roche) and another $2.8M from the Jewish General Hospital Foundation, and nearly $2
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies, sales were 6% lower when reported in CHFPharmaceuticals Division base business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, su
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGF